Abstract | PURPOSE: We evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of intravenous (IV) inclacumab, a fully human IgG4 anti- P-selectin monoclonal antibody in development for the treatment of sickle cell disease, at doses up to and exceeding those previously tested in healthy individuals. METHODS: In this phase 1, open-label, single-ascending-dose study, 15 healthy participants were enrolled into cohorts receiving 20 mg/kg (n = 6) or 40 mg/kg (n = 9) IV inclacumab and observed for up to 29 weeks post-dose. Safety, PK parameters, thrombin receptor-activating peptide (TRAP)-activated platelet-leukocyte aggregate (PLA) formation, P-selectin inhibition, plasma soluble P-selectin, and anti- drug antibodies were characterized. RESULTS: Two inclacumab-related treatment-emergent adverse events were reported in 1 participant; no dose-limiting toxicities were observed. Plasma PK parameters were generally dose-proportional, with a terminal half-life of 13 to 17 days. Mean TRAP-activated PLA formation decreased within 3 h from the start of infusion, and inhibition was sustained for ~ 23 weeks. Mean P-selectin inhibition > 90% was observed up to 12 weeks post-dose. The mean ratio of free to total soluble P-selectin decreased rapidly from pre-dose to end of infusion, then increased gradually to 78% of the baseline ratio by week 29. Treatment-emergent anti- drug antibodies were observed in 2 of 15 participants (13%), without apparent impact on safety, PK, or PD. CONCLUSIONS:
Inclacumab was well tolerated, with PK as expected for a monoclonal antibody against a membrane-bound target and a long duration of PD effects after both single IV doses, supporting a prolonged dosing interval. TRIAL REGISTRATION: ACTRN12620001156976; registered November 4, 2020.
|
Authors | Christina Lourdes Mayer, Kathleen Koeck, Margot Hottmann, Andrew Redfern, Mark Davis, Aline Barth, Xin Geng, Carolyn Hoppe, Patrick Yue |
Journal | European journal of clinical pharmacology
(Eur J Clin Pharmacol)
Vol. 79
Issue 9
Pg. 1219-1228
(Sep 2023)
ISSN: 1432-1041 [Electronic] Germany |
PMID | 37436495
(Publication Type: Clinical Trial, Phase I, Journal Article)
|
Copyright | © 2023. The Author(s). |
Chemical References |
- inclacumab
- Antibodies, Monoclonal
- Selectins
- Polyesters
|
Topics |
- Humans
- Healthy Volunteers
- Antibodies, Monoclonal
(adverse effects)
- Anemia, Sickle Cell
(drug therapy, chemically induced)
- Selectins
- Polyesters
- Double-Blind Method
- Dose-Response Relationship, Drug
|